Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
AssigneePaul G. Richardson
InventorsSarah MCMAHON, Yasuhiro OKI
Life of this patent
Estimating the term…
Abstract
The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.
Claims25
A method of preventing or treating CAR-T cell related encephalopathy syndrome (CRES) (ICANS) in a patient in need thereof comprising administering a therapeutically effective amount of defibrotide to the patient.
A method of decreasing serum biomarker levels associated with cytokine release syndrome (CRS) or CAR-T cell related encephalopathy syndrome (CRES) (ICANS) in a patient diagnosed with CRS or CRES (ICANS) comprising administering a therapeutically effective amount of defibrotide to the patient.
A method of preventing or treating cytokine release syndrome (CRS) or CAR-T cell related encephalopathy syndrome (CRES) (ICANS) in a patient diagnosed with an infection comprising administering a therapeutically effective amount of defibrotide to the patient.
A method of reducing endothelial cell damage associated with cytokine release syndrome (CRS) or CAR-T cell related encephalopathy syndrome (CRES) (ICANS) in a patient in need thereof comprising administering a therapeutically effective amount of defibrotide to the patient.
Dependencies are inferred from the claim text.